The pharmacology study of a new recombinant TNF receptor-hyFc fusion protein

Biologicals

Volumn 41, Issue 2, 2013, Pages 77-83

  Lee, Jung Hwan ^a,d   Cho, Jong Ho ^a   Yeo, Jiwoo ^a   Lee, Sung Hee ^a   Yang, Se Hwan ^b   Sung, Young Chul ^b,c   Kang, Ju Hee ^d   Park, Chang Shin ^d  

^a Dong A Pharmaceutical Company   (South Korea)

^b POSTECH Biotech Center   (South Korea)

^c Pohang University of Science and Technology (POSTECH)   (South Korea)

^d Inha University School of Medicine   (South Korea)

Author keywords

Fc fusion protein; Hybrid Fc; TNF blocker; TNF ; TNFR hyFc

Indexed keywords

ANTIINFLAMMATORY AGENT; ETANERCEPT; IMMUNOGLOBULIN D; IMMUNOGLOBULIN G4; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR HYBRID FC FUSION PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTHRITIS; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG HALF LIFE; DRUG MECHANISM; DRUG STRUCTURE; FEMALE; HUMAN; HUMAN CELL; IMMUNOGLOBULIN STRUCTURE; MALE; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEPTIC SHOCK;

ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, EXPERIMENTAL; CELL LINE, TUMOR; CHO CELLS; CRICETINAE; CRICETULUS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; IMMUNOGLOBULIN G; LIPOPOLYSACCHARIDES; MACACA FASCICULARIS; METABOLIC CLEARANCE RATE; MICE; MICE, INBRED BALB C; MICE, INBRED DBA; NEUTRALIZATION TESTS; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT FUSION PROTEINS; SHOCK, SEPTIC; SURVIVAL RATE; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

MACACA FASCICULARIS;

EID: 84875254370     PISSN: 10451056     EISSN: 10958320     Source Type: Journal    
DOI: 10.1016/j.biologicals.2012.09.001     Document Type: Article

References (35)

1. Tracey D., Klareskog L., Sasso E.H., Salfeld J.G., Tak P.P. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008, 117:244-279.
2. Scallon B.J., Trinh H., Nedelman M., Brennan F.M., Feldmann M., Ghrayeb J. Functional comparisons of different tumor necrosis factor receptor/IgG fusion protein. Cytokine 1995, 7:759-770.
3. Cunnane G., Doran M., Bresnihan B. Infections and biological therapy in rheumatoid arthritis. Best Pract Res Clin Rheumatol 2003, 17:345-363.
4. Nestorov I. Clinical pharmacokinetics of TNF antagonist: how do they differ?. Semin Arthritis Rheum 2004, 34:12-18.
5. Goffe B., Cather J.C. Etanercept: an overview. J Am Acad Dermatol 2003, 49:s105-s111.
6. Schriebl K., Trummer E., Lattenmayer C., Weik R., Kunert R., Muller D., et al. Biochemical characterization of rhEpo-Fc fusion protein expressed in CHO cells. Protein Expr Purif 2006, 49:265-275.
7. Zhang M., Yu D., Yang C., Xia Q., Li W., Liu B. The pharmacology study of a new recombinant human VEGF-Fc fusion protein on experimental choroidal neovascularization. Pharm Res 2009, 26:204-210.
8. Soltani N., Kimar M., Glinka Y., Prud'homme, Wang Q. In vivo expression of GLP-1/IgG-Fc fusion protein enhanced beta-cell mass and protects against streptozotocin-induced diabetes. Gene Ther 2007, 14:981-988.
9. Chamow S.M., Ashkenazi A. Immunoadhesions: principles and applications. Trends Biotechnol 1996, 14:52-60.
10. Mariette X. Emerging biological therapies in rheumatoid arthritis. Joint Bone Spine 2004, 71:470-474.
11. Weinberg J.M. An overview of infliximab, etanercept, efalizumab, and alefacept as biologic therapy for psoriasis. Clin Ther 2003, 25:2487-2505.
12. Idusogie E.E., Wong P.Y., Presta L.G., Gazzano-Santoro H., Totpal K., Ultsch M., et al. Engineered antibodies with increased activity to recruit complement. J Immunol 2001, 166:2571-2575.
13. Schroeder H., Cavacini L. Structure and function of immunoglobulins. J Allergy Clin Immunol 2010, 125:41-52.
14. Liu X.Y., Pop L.M., Vitetta E.S. Engineering therapeutic monoclonal antibodies. Immunol Rev 2008, 222:9-27.
15. Presta L.G. Selection, design, and engineering of therapeutic antibodies. J Allergy Clin Immunol 2005, 116:731-736. quiz 737.
16. Schuurman J., Perdk G.J., Gorter A.D., Aalberse R.C. The inter-heavy chain disulfide bonds of IgG4 are in equilibrium with intra-chain disulfide bonds. Mol Immunol 2001, 38:1-8.
17. An Z., Forrest G., Moore R., Cukan M., Haytko P., Huang L., et al. IgG2m4, an engineered antibody isotope with reduced Fc function. Mabs 2009, 1:572-579.
18. Rother R.P., Mojcik S.A., Brodsky R.A., Bell L. Discovery and development of the complement inhibitor eculizumab for the treatment of paradoxymal nocturnal hemoglobinuria. Nat Biotechnol 2007, 25:1256-1264.
19. Im S.J., Yang S.I., Yang S.H., Choi D.H., Choi S.Y., Kim H.S., et al. Natural form of noncytolytic flexible human Fc as a long-acting carrier of agonistic ligand, erythropoietin. Plos One 2011, 6:E24574.
20. Capon D.J., Kaneko N., Yoshimori T., Shimada T., Wurm F.M., Hwang P.K., et al. Flexible antibodies with nonprotein hinge. Proc Jpn Acad Ser B Phys Biol Sci 2011, 87:603-616.
21. Mohler K.M., Torrance D.S., Smith C.A., Goodwin R.G., Stremler K.E., Fung V.P., et al. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 1993, 151:1548-1561.
22. Wooley P.H. Collagen-induced arthritis in the mouse. Methods Enzymol 1983, 162:361-373.
23. Taylor P.C. Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseases. Curr Opin Pharmacol 2010, 10:308-315.
24. Kaymakcalan Z., Sakorafas P., Bose S., Scesney S., Xiong L., Hanzatian D.K., et al. Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor. Clin Immunol 2009, 131:308-316.
25. Ghetie V., Ward E.S. FcRn: the MHC class I-related receptor that is more than an IgG transporter. Immunol Today 1997, 18:592-598.
26. Roux K.H., Strelets L., Brekke O.H., Michaelesn T.E. Comparision of the ability of human IgG3 hinge mutants, IgM, IgE, and IgA2, to form small immune complexes: a role for flexibility and geometry. Immunology 1998, 161:4083-4090.
27. Loset G.A., Roux K.H., Zhu P., Michaelsen T.E., Standlie I. Differential segmental flexibility and reach dictate the antigen binding mode of chimeric igD and IgM: implications for the function of the B cell receptor. J Immunol 2004, 172:2925-2934.
28. Chen K., Cerutti A. The function and regulation of immunoglobulin D. Curr Opin Immunol 2011, 23:345-352.
29. Flick D.A., Gifford G.E. Comparison of in vitro cell cytotoxic assays for tumor necrosis factor. J Immunol Meth 1984, 68:167-175.
30. Mohler K.M., Butler L.D. Quantitation of cytokine mRNA levels utilizing the reverse transcriptase polymerase chain reaction following primary antigen specific sensitization in vivo. I. Verification of linearity, reproducibility and specificity. Mol Immunol 1991, 28:437-447.
31. Cooper W.O., Fava R.A., Gates C.A., Cremer M.A., Townes A.S. Acceleration of onset of collagen-induced arthritis by intra-articular injection of tumour necrosis factor or transforming growth factor-beta. Clin Exp Immunol 1992, 89:244-250.
32. Thorbecke G.J., Shah R., leu C.H., Kuruvilla A.P., Hardison A.M., Palladino M.A. Involvement of endogenous tumor necrosis factor alpha and transforming growth factor beta during induction of collagen type II arthritis in mice. Proc Natl Acad Sci U S A 1992, 89:7375-7379.
33. Brahn E., Peacock D.J., Banquerigo M.L., Liu D.Y. Effects of tumor necrosis factor alpha (TNF-alpha) on collagen arthritis. Lymphokine Cytokine Res 1992, 11:253-256.
34. Wooley P.H., Dutcher J., Widmer M.B., Gillis S. Influence of a recombinant human soluble tumor necrosis factor receptor FC fusion protein on type II collagen-induced arthritis in mice. J Immunol 1993, 151:6602-6607.
35. Lee J., Yeo J., Park H.S., Sung G., Lee S.H., Yang S.H., et al. Biochemical characterization of a new recombinant TNF receptor-hyFc fusion protein expressed in CHO cells. Protein Expr Purif 2013, 87:17-26.